Abstract DDT02-04: SGN-CD33A: Preclinical and phase 1 interim clinical trial results of a CD33-directed PBD dimer antibody-drug conjugate for the treatment of acute myeloid leukemia (AML)

2015 ◽  
Author(s):  
Dana A. Kennedy ◽  
Stephen C. Alley ◽  
Baiteng Zhao ◽  
Eric J. Feldman ◽  
Megan O'Meara ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Phase 1 ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Clinical Trial Results ◽  
Acute Myeloid ◽  
Antibody Drug

scholarly journals An Anti–CLL-1 Antibody–Drug Conjugate for the Treatment of Acute Myeloid Leukemia

2018 ◽  
Vol 25 (4) ◽  
pp. 1358-1368 ◽  
Author(s):  
Bing Zheng ◽  
Shang-Fan Yu ◽  
Geoffrey del Rosario ◽  
Steven R. Leong ◽  
Genee Y. Lee ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Acute Myeloid ◽  
Antibody Drug

scholarly journals CLT030, a leukemic stem cell–targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia

2018 ◽  
Vol 2 (14) ◽  
pp. 1738-1749 ◽  
Author(s):  
Ying-Ping Jiang ◽  
Bob Y. Liu ◽  
Quan Zheng ◽  
Swapna Panuganti ◽  
Ruoying Chen ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Myeloid Leukemia ◽  
Leukemic Stem Cell ◽  
Cell Targeting ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Key Points ◽  
Acute Myeloid ◽  
Antibody Drug

Key Points CLL1-ADC targets both AML blasts and LSCs. Unlike CD33-ADC, CLL1-ADC does not affect normal HSCs.

scholarly journals Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia

2017 ◽  
Vol 17 (2) ◽  
pp. 554-564 ◽  
Author(s):  
Fu Li ◽  
May Kung Sutherland ◽  
Changpu Yu ◽  
Roland B. Walter ◽  
Lori Westendorf ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Acute Myeloid ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document